Esperion Therapeutics Inc (ESPR)

May 20, 2025

Esperion at H.C. Wainwright Conference: Strategic Growth and Future Plans - Investing.com

May 20, 2025

May 20, 2025

Esperion to Participate in Upcoming June Investor Conferences - GlobeNewswire

May 20, 2025

May 15, 2025

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival - insights.citeline.com

May 15, 2025

May 12, 2025

Esperion Therapeutics, Micro Labs Settle Generic Nexletol Patent Dispute - marketscreener.com

May 12, 2025

May 12, 2025

Esperion reaches settlement agreement with Micro Labs - TipRanks

May 12, 2025

May 12, 2025

Esperion Settles Patent Litigation With Micro Labs For Generic Nexletol - Nasdaq

May 12, 2025

May 12, 2025

Esperion (ESPR) Reaches Settlement with Micro Labs Over Patent D - GuruFocus

May 12, 2025

May 12, 2025

Esperion Reaches Settlement Agreement With ANDA Filer Not To Market Generic Version Of Nexletol - marketscreener.com

May 12, 2025

May 12, 2025

Esperion Settles Patent Litigation with Micro Labs Regarding NEXLETOL Generic Marketing Rights - Nasdaq

May 12, 2025

May 12, 2025

Esperion Reaches Settlement Agreement with ANDA Filer Not - GlobeNewswire

May 12, 2025

May 12, 2025

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - The Globe and Mail

May 12, 2025

May 09, 2025

ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - The Globe and Mail

May 09, 2025

May 09, 2025

HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines - Yahoo Finance

May 09, 2025

May 09, 2025

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference - GlobeNewswire

May 09, 2025

May 08, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

May 08, 2025

May 08, 2025

Esperion at The Citizens JMP Life Sciences Conference: Strategic Growth Insights - Investing.com India

May 08, 2025

May 08, 2025

Esperion Therapeutics Q1 2025 Earnings Preview - MSN

May 08, 2025

May 08, 2025

Esperion and HLS partner to commercialize heart disease treatments in Canada - Seeking Alpha

May 08, 2025

May 08, 2025

ESPR Secures Canadian Distribution Deal for NEXLETOL and NEXLIZE - GuruFocus

May 08, 2025

May 08, 2025

Esperion Therapeutics Enters License and Distribution Agreement with HLS Therapeutics - marketscreener.com

May 08, 2025

May 08, 2025

HLS Therapeutics Partners with Esperion to Bring Cardiovascular Treatments to Canada - TipRanks

May 08, 2025

May 08, 2025

Esperion secures Canadian rights deal for heart drugs - Investing.com

May 08, 2025

May 08, 2025

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada - The Manila Times

May 08, 2025

May 08, 2025

Esperion Enters License Agreement with HLS Therapeutics to Expand Access to Bempedoic Acid Products in Canada - Nasdaq

May 08, 2025

May 08, 2025

Esperion secures Canadian rights deal for heart drugs By Investing.com - Investing.com Canada

May 08, 2025

May 08, 2025

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and ... - Bluefield Daily Telegraph

May 08, 2025

May 08, 2025

Esperion Therapeutics (ESPR) Partners with HLS Therapeutics to Commercialize NEXLETOL and NEXLIZET in Canada - StreetInsider

May 08, 2025

May 08, 2025

HLS Therapeutics Announces Q1 2025 Financial Results - Yahoo Finance

May 08, 2025

May 08, 2025

Esperion Partners with HLS Therapeutics to Commercialize - GlobeNewswire

May 08, 2025

May 08, 2025

Esperion outlines Q2 prescription growth, targets triple combo launch by 2027 - MSN

May 08, 2025

May 07, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 07, 2025

May 07, 2025

Esperion Therapeutics: Q1 Earnings Snapshot - Norwalk Hour

May 07, 2025

May 06, 2025

Esperion Therapeutics Reports Strong Q1 2025 Earnings - TipRanks

May 06, 2025

May 06, 2025

Earnings call transcript: Esperion Q1 2025 misses EPS forecast, revenue grows - Investing.com Nigeria

May 06, 2025

May 06, 2025

Esperion Therapeutics (ESPR) Reports Strong Q1 2025 Revenue Grow - GuruFocus

May 06, 2025

May 06, 2025

Esperion Therapeutics (ESPR) Reports Strong Q1 2025 Revenue Growth - GuruFocus

May 06, 2025

May 06, 2025

Esperion Q1 2025 slides: U.S. product sales surge 41% amid strategic expansion - Investing.com India

May 06, 2025

May 06, 2025

Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 06, 2025

May 06, 2025

ESPERION THERAPEUTICS Earnings Results: $ESPR Reports Quarterly Earnings - Nasdaq

May 06, 2025

May 06, 2025

Esperion Reports First Quarter 2025 Financial Results - The Manila Times

May 06, 2025

May 06, 2025

BRIEF-Esperion Therapeutics Q1 Basic EPS USD -0.21 - TradingView

May 06, 2025

May 02, 2025

Esperion Therapeutics Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView

May 02, 2025

Apr 29, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 29, 2025

Apr 29, 2025

Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Apr 29, 2025